Trial Profile

Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Gastrointestinal cancer; Neuroendocrine carcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms MAVERIC

Most Recent Events

24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
24 Oct 2023 Primary endpoint has been met (PFS), as per Results presented at the 48th European Society for Medical Oncology Congress
26 May 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com